Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kontafarma China HoldingsHKSE:01312 +3.45% FCF Margin % is 2.89% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 962 Drug Manufacturers companies, Kontafarma China Holdings ranks better than 59.36% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kontafarma China Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kontafarma China Holdings FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kontafarma China Holdings's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Kontafarma China Holdings's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kontafarma China Holdings (HKSE:01312) has a FCF Margin % of 2.89% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kontafarma China Holdings and its competitors. According to the industry distribution chart, Kontafarma China Holdings ranks #391 out of 962 companies in the Drug Manufacturers industry, placing it in the top 40.6%.
Is Kontafarma China Holdings' FCF Margin % too high?
Kontafarma China Holdings' current FCF Margin % is 2.89%. The Drug Manufacturers industry median FCF Margin % is 2.48. Kontafarma China Holdings' value of 2.89% is 16.5% above this industry median. Based on the distribution chart, Kontafarma China Holdings ranks #391 out of 962 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Kontafarma China Holdings' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kontafarma China Holdings ranks #391 out of 962 companies for FCF Margin %. This puts Kontafarma China Holdings in the upper half of its industry. The industry median FCF Margin % is 2.48. Kontafarma China Holdings' value of 2.89% is 16.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.48, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kontafarma China Holdings's current FCF Margin % of 2.89% is 16.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Kontafarma China Holdings and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kontafarma China Holdings's current FCF Margin % is 2.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kontafarma China Holdings stock overvalued right now?
Based on GuruFocus' analysis, Kontafarma China Holdings (HKSE:01312) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.04, compared to a current price of HK$0.03 — trading 25% below its estimated fair value. The current FCF Margin % is 2.89% and 16.5% above the Drug Manufacturers industry median of 2.48. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Kontafarma China Holdings (HKSE:01312), the current FCF Margin % is 2.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kontafarma China Holdings Ltd and its subsidiaries are principally engaged in the pharmaceutical and fitness business. The Group manufactures and sells prescription drugs, including chemical drugs, traditional Chinese medicine prescriptions, active pharmaceutical ingredients, and API intermediates in China, and operates fitness centres, provides fitness and health consultation services, and operates a franchise business for royalty fee income. Its segments are the pharmaceutical business, which generates maximum revenue, and the fitness business. The Group operates in Mainland China, Singapore, Taiwan, and other regions, with maximum revenue from Mainland China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01312 has been successfully added to your 
